MHE Test Advertising Article Page

If approved, Wegovy would be the first oral GLP-1 drug to treat obesity.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

A new report suggests combining the antimalarial drug with aminoglycosides could enhance the latter’s efficacy, which could also have important safety implications.

Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.